Combination of IFNα and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction

BACKGROUND: BCG is a prototypal cancer immunotherapeutic factor currently approved of bladder cancer. In attempt to further enhance the effectiveness of immunotherapy of bladder cancer and, potentially, other malignancies, we evaluated the impact of BCG on local production of chemokines attracting t...

Descripción completa

Detalles Bibliográficos
Autores principales: Muthuswamy, Ravikumar, Wang, Liwen, Pitteroff, Jamie, Gingrich, Jeffrey R, Kalinski, Pawel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371844/
https://www.ncbi.nlm.nih.gov/pubmed/25806105
http://dx.doi.org/10.1186/s40425-015-0050-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371844/
https://www.ncbi.nlm.nih.gov/pubmed/25806105
http://dx.doi.org/10.1186/s40425-015-0050-8

Ejemplares similares